Amendment to Regulation (EC) 816/2006
This procedure concerns the possibility of granting compulsory licenses for patents related to crisis management. It aims to ensure access to essential technologies during emergencies, potentially impacting the pharmaceutical sector.
The regulation amends existing rules on the European patent, affecting intellectual property rights for medicines and other crisis-related products. This could influence innovation and access for patients and public health bodies.
Documents
Amendment to Regulation (EC) 816/2006
proposal · EN · 2026-05-02
Amendment to Regulation (EC) 816/2006
proposal · EN · 2026-05-02
Amendment to Regulation (EC) 816/2006
report · EN · 2026-05-02
Amendment to Regulation (EC) 816/2006
position · EN · 2026-05-02
Amendment to Regulation (EC) 816/2006
position · EN · 2026-05-02
Amendment to Regulation (EC) 816/2006
report · EN · 2026-05-02
Amendment to Regulation (EC) 816/2006
report · EN · 2026-05-02
Amendment to Regulation (EC) 816/2006
report · EN · 2026-05-02
Amendment to Regulation (EC) 816/2006
report · EN · 2026-05-02